Xponance Inc. Raises Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Xponance Inc. increased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,763 shares of the biopharmaceutical company’s stock after purchasing an additional 1,189 shares during the period. Xponance Inc.’s holdings in Catalyst Pharmaceuticals were worth $392,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in CPRX. abrdn plc purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth about $10,115,000. Raymond James Financial Inc. purchased a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $6,887,000. Skandinaviska Enskilda Banken AB publ grew its position in Catalyst Pharmaceuticals by 74.3% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock valued at $15,421,000 after acquiring an additional 312,000 shares in the last quarter. Jane Street Group LLC raised its stake in shares of Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after purchasing an additional 285,564 shares during the period. Finally, Walleye Capital LLC acquired a new position in shares of Catalyst Pharmaceuticals during the third quarter worth $4,936,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

CPRX has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Finally, Bank of America reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $32.29.

Insiders Place Their Bets

In other news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by corporate insiders.

Catalyst Pharmaceuticals Trading Down 2.2 %

Shares of CPRX opened at $25.15 on Thursday. The firm has a market cap of $3.05 billion, a price-to-earnings ratio of 21.31, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16. The stock has a 50 day moving average of $22.57 and a 200-day moving average of $21.74.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.